Setting our strategic vision for the next generation TLR9 immunotherapy platform – introducing MOLOGEN’s new CEO Dr. Stefan M. Manth
Setting our strategic vision for the next generation TLR9 immunotherapy platform – introducing MOLOGEN’s new CEO Dr. Stefan M. Manth
Dear Sir or Madam,
Dr. Stefan M. Manth joined the German immunotherapy pioneer MOLOGEN AG as its new CEO, beginning of May after 5 years on its Supervisory Board. Dr. Manth would like to take the opportunity to introduce himself as well as his vision and strategy for MOLOGEN’s pipeline which includes lefitolimod – a best-in-class TLR9 agonist currently tested in a phase III pivotal study in colorectal cancer and EnanDIM® which delivers a next-generation pipeline of DNA-based TLR9 candidates with excellent preclinical data in immuno-oncology and possibly HIV.
“TLR9 activators have been enjoying a renaissance over the past few years and rightly so, after previously languishing on the dark side of the moon. Our next generation of ‘homebrew’ TLR9 agonists gives us the opportunity to launch a clinical development program directly targeted at both the changed competitive and therapeutic environment. The key word here is ‘combination therapy’. A development strategy which also takes into account lessons learned from our lefitolimod program.”
Dr. Stefan M. Manth, CEO of MOLOGEN AG
We would like to offer you the opportunity to speak with Dr. Manth to learn more about his vision and strategy for MOLOGEN over the coming few days.
About MOLOGEN
MOLOGEN is a publicly listed German-based immunotherapy pioneer founded in 1998. It is one of very few German biotech companies offering an advanced pipeline of unique active agents and technologies for the treatment of cancer and infectious diseases. The focus of MOLOGEN’s development is on DNA-based TLR9 agonists, where it has consistently been ahead of the course. This includes the immunotherapy lefitolimod and its next generation molecules EnanDIM®, building the foundation for a next generation immunotherapy platform in areas of unmet need.
Forthcoming milestones include: the read-out of the phase III pivotal study IMPALA in the indication of colorectal cancer as well as the start of the TITAN study in HIV.
A Pioneer in immunotherapy building the foundation for a next generation immunotherapy platform
- MOLOGEN’s lead product, the best-in-class TLR9 agonist lefitolimod, is the most advanced product candidate among the TLR9 agonists in the world
- Thus, lefitolimod builds the foundation for a next generation immunotherapy platform for the treatment of different cancer types and HIV
- Various studies have proven that lefitolimod triggers a broad immune response and has an excellent safety profile
- Important milestone ahead: Results of IMPALA Phase III pivotal study in colorectal cancer, to be published in August
- lefitolimod is the perfect partner for anti-cancer combination immunotherapies
- Immunotherapies have enormous market potential, especially for serious and so far incurable diseases such as cancer and HIV
- Promising partnerships with Aarhus University sponsored by GILEAD
A Promising product pipeline providing next frontier in immune-oncology and a possible functional cure in HIV/AIDS
- lefitolimod successor molecules EnanDIM® are a groundbreaking development in cancer immunotherapy and for a potential functional cure for HIV
- EnanDIM® offers next-generation pipeline of DNA-based TLR9 candidates with excellent preclinical data in immuno-oncology and possibly HIV
- Multi-national TITAN study in the indication HIV is about to start; Evaluation of the Phase II study expected in 2021 to achieve Proof of Concept by 2022.
Please see www.mologen.com for further information
About Dr. Stefan M. Manth
Dr. Stefan M. Manth, has over 35 years of experience in the pharmaceutical industry with two decades of management experience within the Roche Group. He was a key executive player in the successful establishment and expansion of the Oncology franchise at Roche and Chugai. The Roche Group is the undisputed world market leader in oncology. Dr Manth knows MOLOGEN very well and took on the position of CEO as well as the tasks of the CFO of MOLOGEN after having been member of the Company’s Scientific Advisory Board between 2011 and September 2013 and former Deputy Chairman of the Supervisory Board of MOLOGEN since August 2014 until his transition into the executive role on May 1, 2019.
Picture of Dr. Stefan M. Manth
Contact:
MOLOGEN AG
Theresa Koster
Phone: +49-30-84 17 88-37
Mail: koster@mologen.com
